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Abstract
Background: Idiopathic Pulmonary Fibrosis (IPF) is a progressive diffuse disease involving the lung
parenchyma. Despite recent advances, the molecular mechanisms of the initiation and progression
of this disease remain elusive. Previous studies have demonstrated TGFβ1 as a key effector
cytokine in the development of lung fibrosis.
Methods: In this study we have used a transgenic mouse based strategy to identify the effect of
overexpression of this key effector mediator on the development of pulmonary fibrosis in response
to exogenous injury. We bred two lines (line 25 and 18) of transgenic mice (Tr+) that
overexpressed active TGFβ1. Three-month old transgenic and wild type mice were subsequently
wounded with intraperitoneal bleomycin. Mice were sacrificed at 6 weeks post-bleomycin and their
lungs analysed histologically and biochemically.
Results: The severity of lung fibrosis was significantly greater in the Tr+ mice compared to the
wild type mice. Using an oligonucleotide microarray based strategy we identified discrete patterns
of gene expression contributing to TGFβ1 associated pulmonary fibrosis.
Conclusion:  This data emphasises the importance of a host predisposition in the form of
endogenous TGFβ1, in the development of pulmonary fibrosis in response to an exogenous injury.
Background
Idiopathic pulmonary fibrosis (IPF) is a progressive dif-
fuse fibrotic process involving the lung parenchyma. It is
a chronic, progressively debilitating and ultimately fatal
disorder [1]. Treatment options are limited and lung
transplantation may be offered to a minority of patients.
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Recent studies have demonstrated that the outcome from
disease was determined by the burden of collections of
activated fibroblasts, fibroblastic foci, and not the extent
of histological inflammation [2-5].
In IPF, exogenous mediators are thought to precipitate the
lung injury, and in synergy with genetic factors contribute
to the disease. These genetic factors are increasingly
thought to play an important role, with familial pattern-
ing of IPF already described. Efforts to identify genetic loci
linked to this disease have thus far been inconclusive [6].
Extensive experimental evidence has identified, TGFβ1 as
a central regulator of tissue fibrosis at multiple sites. Evi-
dence from studies of fibrotic disorders, including renal
and liver fibrosis, supports that TGFβ1 may play a novel
role in fibrogenesis by promoting epithelial-mesenchy-
mal transition (EMT) and activating fibroblasts to myofi-
broblasts [7-9]. In mature epithelial cells, TGFβ1 can
initiate EMT through activation of intracellular signalling
molecules [10,11]. EMT contributes to the degeneration
of epithelial structures and to the generation of fibroblasts
in chronic fibrotic disorders [8,12,13]. While targeted
overproduction of TGF-β1 is associated with an increase
in pulmonary fibrosis, antagonising its effects prevent the
fibrotic process [14]. Reviewing potential candidate path-
ways that might offer novel therapeutic targets to treat IPF,
Antoniou KM reported antibodies to TGFβ1 significantly
reduced the cytokine experimental lung and kidney fibro-
sis and a receptor antagonist to this cytokine decreased
accumulation of lung collagen induced by bleomycin
[15]. Several approaches to reduce TGFβ1 levels have also
been evaluated in human tissue in vivo, showing downreg-
ulation of the fibrotic process by IFN-1b, which may occur
both directly and indirectly by modification of the fibrob-
last response to reduced TGFβ1. [16,17].
In this study we evaluated TGF-β1 gene overexpression in
isolation and the impact of an exogenous injury in the set-
ting of a host genetically predisposed by endogenous TGF-
β1 gene overexpression. Furthermore we sought to charac-
terise the molecular mechanisms underpinning the devel-
opment of the resultant fibrosis utilising gene array
techniques.
Methods
TGFβ1 transgenic mice
The mice were originally engineered by microinjection of
a DNA fragment into the nuclei of one-cell mouse
embryos. The DNA fragment containing an altered por-
cine TGFβ1 cDNA associated with an albumin promoter
to ensure the preferential expression of the active form of
TGFβ1 from the liver, with resultant high circulating levels
[18]. Mouse embryos were obtained from mating of F1
hybrid mice (C57BL6 × CBA background). Two lines of
mice (line 18 and line 25) were purchased (Nancy Sand-
erson, National Institute Of Health, Bethesda, MD, USA).
The transgene was expressed in both sexes of the line 18
mice. The mice were bred by crossing a positive with a
wild type animal. In the line 25 mice, only the male mice
expressed the transgene. Therefore, the mice were bred by
setting up a harem consisting of a positive male animal
and three F1 females. Mice were housed under pathogen-
free conditions and husbanded according to Home Office
regulations.
On day 0 mice were given intraperitoneal bleomycin
(BLM) or phosphate buffer solution (PBS) in three
divided doses (0.5 ml volume) over a course of 5 days.
They were observed on a daily basis and sacrificed on day
42. Mice were divided into 6 groups (n = 8/group).
Characterisation of TGFβ1 Tr+ transgenic mice
Mouse-tail snips, measuring approximately 0.25 cm, were
incubated with proteinase K overnight at 55°C and DNA
was extracted the following day using Phenol/Chloro-
form/Isoamylalcohol method followed by washing-step
in 70% ethanol.
TGFβ1 quantification was performed using a PAI-1/Luci-
ferase assay (PAIL). PAIL assay is a quantitative bioassay
based upon active TGFβ's ability to stimulate the expres-
sion of Plasminogen Activator Inhibitor 1 (PAI-1) [19].
The assay uses mink lung epithelial cells (MLEC's) (a kind
gift from Dr Dan Rifkin, New York University Medical
Center, New York), which have been stably transfected
with a gene for Luciferase activity and its expression is reg-
ulated and promoted by a truncated PAI-1 promoter con-
struct. TGFβ1 therefore regulates Luciferase activity via
PAI-1 promoter. Luciferase activity in MLEC cell lysates
was measured in a luminometer.
Histological analysis
Liver and lung tissue sections were stained with haema-
toxylin and eosin and Masson's trichrome, which deter-
mines collagen deposition and localization. Lung fibrosis
was graded histologically by an established scoring system
[20].
Immunohistochemical analysis was performed as previ-
ously described [21]. In brief, paraffin sections were
stained with rabbit anti-reticulin (Sigma, UK), rabbit anti-
TGFβ1 (Santa Cruz, CA, USA) and its receptors (TGFβ1R1,
TGFβ1R2, TGFβ1R3) (Santa Cruz, CA, USA) (1:100).
Antibody binding was visualized using a biotinylated sec-
ondary antibody, avidine conjugated peroxidase (ABC
method; Vector Laboratories) and 3,3' diaminobenzidine
tetrachloride (DAB) as a substrate and hematoxylin as
counterstain.Journal of Inflammation 2007, 4:18 http://www.journal-inflammation.com/content/4/1/18
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Collagen assay
For collagen determination we employed a hydroxypro-
line assay technique. Briefly after death, lungs were
removed and weighed. 6 M hydrochloric acid was added
to each sample, then sealed and placed in an oven over-
night at 110°C. Excess acid was removed by evaporation
and hydrolyzed samples were dissolved in 1 ml of PBS.
The samples were aliquoted adding Chloramine T reagent
equally to each sample. After 20 minutes of mixing, 1 ml
of p-DAB reagent (p-dimethyl-amino-benzaldehyde) was
added and the mixture incubated at 60°C. The colour sig-
nals were measured in a spectrophotometer at 550 nm,
and compared to a standard curve.
Microarray analysis
RNA isolation, cDNA synthesis, in vitro transcription and
microarray analysis were performed as previously
reported [22]. Arrays were scanned with a confocal scan-
ner (Affymetrix). All in vitro time points were microar-
rayed in duplicate.
Image files were obtained through Affymetrix GeneChip
software (MAS5). Subsequently robust multichip analysis
(RMA) was performed [23,24]. Expression data was fur-
ther probed to identify those genes whose expression is
altered [25]. Expression data following injury was com-
pared to control and a signal log ratio of 0.6 or greater
(equivalent to a fold change in expression of 1.5 or
greater) was taken to identify significant differential regu-
lation. Using normalised RMA values, Unsupervised Aver-
age Linkage Hierarchical Cluster Analysis was performed
[26]. Functional annotation of differentially expressed
genes was curated via the publicly available Onto-Com-
pare and Gene-Ontology (GO) databases [27].
Results and discussion
TGF-β1 transgenic mice develop severe liver fibrosis
Following breeding, TGFβ1 expression was confirmed by
PCR amplification in Tr+ TGFβ1 transgenic mice (Figure
1a). To determine the effect of the TGFβ1 transgene in
these mice, serum levels of both total and active TGFβ1
were determined. The Tr+ transgenic mice had higher lev-
els of total TGFβ1 (2.2 ng/ml, SEM 0.23) compared to Tr-
wild types (1.58 ng/ml, SEM 0.39), though this compari-
son did not reach statistical significance (p = 0.16) (Figure
1b); while, Tr+ transgenic mice had higher plasma levels
of active TGFβ1 (mean 98.1 pg/ml, SEM 16.1) compared
to Tr- wild types (mean 9.37, SEM 6.6) (p < 0.01). Individ-
ually, the line 18 mice had a similar level of active TGFβ1
(mean 87 pg/ml, SEM 19.2) to the line 25 mice (105.5 pg/
ml, SEM 24.5) (Figure 1c).
Having demonstrated altered DNA and protein expres-
sion in TGFβ1-transgenic mice we sought to determine
the effect of TGFβ1 overexpression on tissue phenotype.
Tr+ transgenic mouse livers were histologically abnormal
as early as 1 month, though the most marked changes
were seen from 3 months onwards. This consisted of
extensive cellular degeneration, vacuolisation, fibrosis
and architectural disruption (Figure 2a), compared to Tr-
wild type mouse liver (Figure 2b). Staining for the pre-col-
lagen, reticulin signalling was higher in transgenic mice
tissue than wild type, confirming the presence of ongoing
tissue fibrosis (Figure 2c–d). Tissue changes were most
pronounced in the line 25 mice, but also present in line
18 mice, while wild type mice had normal liver architec-
ture and normal reticulin levels.
These data demonstrate overexpression of TGFβ1 in Tr+
transgenic mice and detail the alterations in phenotype,
providing a model for the assessment of the contribution
of this important effector cytokine to the fibrotic milieu in
vivo.
Overexpression of TGFβ1 in the liver leads to a severe liver
fibrosis. Fibrotic liver phenotype presented at 1 month
with the injury being most severe from 3 months
onwards. Of note was the finding of enhanced reticulin
deposition in the fibrotic tissue versus Tr- wild type mice.
These data provide evidence that overexpression of TGFβ1
in mouse liver promotes de novo fibrosis, even in the
absence of other pro-fibrotic stimuli.
Overexpression of TGFβ1 does not cause de novo lung 
fibrosis
Having demonstrated the molecular effect of TGFβ1 over-
expression and its effect on mouse liver we examined the
impact of Tr+ TGFβ1 transgenic expression on mouse
lung. Of note was the finding that transgenic mouse lungs
(Figure 3a) showed no evidence of de novo fibrosis at any
time point studied.
To determine the putative mechanism underpinning this
tissue specific finding we characterised the expression of
TGFβ1 in transgenic mouse lung. Figure 3b shows staining
for active TGFβ1 in lung tissue, providing evidence that
whilst TGFβ1 is present in the lung it does not produce a
fibrotic response. Having determined the presence of
active TGFβ1 in these lungs, expression of TGFβ1 recep-
tors was investigated. Of note was the finding that, Tr+
transgenic mouse lung was found to contain an abun-
dance of both Type I (Figure 3c) and type II (Figure 3d)
TGFβ1 receptors.
These data demonstrate that de novo tissue fibrosis in
response to TGFβ1 overexpression is tissue specific. In the
setting of the lung, active TGFβ1 does not produce a
fibrotic phenotype despite an abundance of both type I
and type II receptors. The data presented herein lend
weight to the hypothesis that TGFβ1 contributes to lungJournal of Inflammation 2007, 4:18 http://www.journal-inflammation.com/content/4/1/18
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fibrosis in vivo through the interplay with other factors,
and is not sufficient, in itself to drive lung fibrosis.
Oligonucleotide microarray analysis identifies distinct 
patterns of gene expression underpinning lung injury
The data generated in the histological studies identified
that TGFβ1 overexpression is insufficient to establish pul-
monary fibrosis. However we determined the effect of a
second insult with bleomycin on TGFβ1- and WT-trans-
genic mice.
To determine the molecular events subserving the TGFβ1
mediated exacerbation of lung fibrosis we utilised an oli-
gonucleotide microarray based strategy to identify altered
key transcripts. Specifically, we probed the molecular con-
tribution to the repetitive injury, namely the expression
changes induced by TGFβ1 overexpression and the expres-
sion changes that result from bleomycin exposure in these
Tr+ transgenic mice. Affymetrix Mouse Genome 430_2
microarrays were used to determine gene expression levels
in lung tissue from a) untreated Tr+ TGFβ1 transgenic
mice b) Tr- wild type mice treated with bleomycin and c)
bleomycin treated Tr+ TGFβ1 transgenic mice, to identify
the overall pattern of gene expression in this experiment.
Significant changes in gene expression were associated
with these tissue cohorts (-0.6 < SLR > 0.6, and p < 0.05)
(Figure 4a). Distinct patterns of coordinate gene expres-
sion were observed throughout the exposures, with sub-
stantial transcriptomic effects in terms of both up and
downregulation of gene expression separating the sample
groups.
Of the 45,101 gene sequences represented on the Affyme-
trix Mouse Genome 430_2 oligonucleotide microarray,
6.2% (2812 genes) were found to be significantly altered
in all three groups. Exposure of Tr+ TGFβ1 transgenic mice
to bleomycin elicited a major gene expression response
with a total of 3.9% significantly altered transcripts (1724
genes) in compare to untreated Tr+ TGFβ1 transgenic
mice. To probe molecular basis of TGFβ1 exacerbation of
Characterisation of TGFβ1 transgenic mice Figure 1
Characterisation of TGFβ1 transgenic mice. A. Expression of the transgene in wild type and both line 18 and line 25 
transgenic mice was assessed by PCR using TGFβ1 sequence specific primers. This figure is a representative agarose gel post 
amplification indicating expression of the TGFβ1 transgene in both line 18 and line 25 Tr+ transgenic mice (Lanes 1 and 2). 
Lanes 3 and 4 show absence of transgene in wild type mice. Figure B and C show PAIL lumineriferase assay results. To deter-
mine the effect of the transgene on circulating TGFβ1, both total (B) and active (C) TGFβ1 concentrations in sera was deter-
mined.Journal of Inflammation 2007, 4:18 http://www.journal-inflammation.com/content/4/1/18
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lung injury the expression profiles of both bleomycin-
treated WT and TGFβ1 transgenic mice were compared,
showing 640 significant gene expression changes between
these groups (1.4% of the transcripts represented on the
microarray) (Figure 4b).
To further annotate the transcriptomic differences
between the study groups' ontological classification of
molecular function was investigated by using Gene Ontol-
ogy database (Figure 4c). By using Gene Ontology data-
base, Bleomycin TR+ vs TR+ altered transcripts were
classified and grouped in functional families in correla-
tion with their significant role in fibrosis development.
Altered fibrosis-associated genes, which drive angiogen-
esis, inflammatory response, immune response and apop-
tosis, in response to bleomycin in TR+ mice were found
dysregulated, as also previously reported [28-30]. In addi-
tion, we found a large number of significantly altered
genes that function in the regulation of cellular morpho-
genesis, development and gene transcription. Bleomycin-
exposed TR+ TGFβ1 transgenic mice show overall altered
gene expression profile which correlate with cellular mor-
TGFβ1 overexpression induces severe liver fibrosis Figure 2
TGFβ1 overexpression induces severe liver fibrosis. A. Shown are representative micrographs following haematoxylin/
eosin staining indicating severe liver fibrosis in TGFβ1 transgene expressing mice. B shows normal Tr- wild type mice liver tis-
sue stained by haematoxylin/eosin. C. The deposition of the pro-collagen, reticulin, was also determined using specific mono-
clonal antibody anty-reticulin by immunohistochemistry in Tr- WT mice liver tissue sections. D. Whilst low abundance staining 
is seen in wild type liver, expression of reticulin is dramatically enhanced in the Tr+ TGFβ1 transgenic mice.Journal of Inflammation 2007, 4:18 http://www.journal-inflammation.com/content/4/1/18
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phogenesis and gene transcription, enhanced cellular
functions which trigger fibrosis development.
Tables 1 and 2 highlight the genes whose mRNA levels
were most strikingly altered in bleomycin injured and Tr+
TGFβ1 transgenic mice.
Table 1 indicates a large number of altered genes, which
are largely recognized as mediators of immunological
function. Further annotation of these upregulated genes
identified a large number of genes involved in cytokine
signalling. Further, the transcripts whose expression was
found to be altered in response to bleomycin exposure
included a large number of extracellular matrix and matrix
regulation associated genes, key effectors molecules in the
development of tissue fibrosis.
TGFβ1 overexpression primes mouse lung for fibrotic 
injury following bleomycin exposure
Having demonstrated that overexpression of TGFβ1,
whilst initiating severe fibrosis in mouse liver, does not
cause de novo lung fibrosis; we determined the effect of
escalating doses of bleomycin on TGFβ1 and WT trans-
genic mice.
Absence of lung fibrosis in TGFβ1 overexpressing mice Figure 3
Absence of lung fibrosis in TGFβ1 overexpressing mice. Figure A shows haematoxylin and eosin staining of Tr+ TGFβ1 
transgenic lung tissue. Of note was the absence of fibrosis in transgenic mice. To determine the molecular events underpinning 
this process we determined the expression of TGFβ1 (B), Type I receptor for TGFβ1 (C) and the TGFβ1 Type II receptor (D) 
by immunohistochemistry. As can be seen TGFβ1 and its receptors are present in abundance in lung tissue from these mice, 
indicating a normal TGFβ1 signalling cascade in Tr+ pulmonary tissue.Journal of Inflammation 2007, 4:18 http://www.journal-inflammation.com/content/4/1/18
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Oligonucleotide microarray analysis reveals coordinate patterns of gene expression in response to bleomycin lung injury Figure 4
Oligonucleotide microarray analysis reveals coordinate patterns of gene expression in response to bleomycin 
lung injury. A. Gene expression in Bleomycin treated Tr- Wild Type (WT BL, WTB1, WTB2) and Tr+ TGFβ1 trasgenic mice 
(TGF BL, TGFBL1, TGFBL2), and untreated Tr+ TGFβ1 trasgenic mice (TGF, TGF1, TGF2) was assessed using Affymetrix 
Mouse Genome 430_2 oligonucleotide microarrays in duplicate (data are reported in the cluster dendogram as single analysis 
and average: cel1, cel2 and average, respectively). Average and actual expression values for all significantly dysregulated genes 
were used as input in unsupervised hierarchical cluster visualization. Shown is a representative cluster dendrograms indicating 
separation of the conditions based on gene expression profiles, highlighting an high homology (based on the t-score) of both 
bleomycin treated group, respect to untreated Tr+ transgenic mice group. Figure B summarises the total number of genes 
found to be significantly altered in each comparison (Tr+ and bleomycin vs Tr- WT and bleomycin; Tr+ and bleomycin vs Tr+; 
Tr+ vs Tr- WT and bleomycin). A high number of altered genes were found to be upregulated and dowwnregulated in bleomy-
cin treated Tr+ vs Tr+ group. C. To further annotate the pulmonary fibrosis associated transcriptome, significantly perturbed 
genes from bleomycin treated Tr+ vs Tr+ group were used as input in searches of the Gene Ontology database to identify the 
biological function of the altered genes.Journal of Inflammation 2007, 4:18 http://www.journal-inflammation.com/content/4/1/18
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Exposure to 1500 IU of bleomycin resulted in 5 mice (Tr+
line 25) developing lung fibrosis compared to only 2 in
the Tr- wild type group. 4500 IU of bleomycin showed
fibrosis in all 8 mice of the Tr+ line 25, compared to 6
mice in the Tr+ line 18 group and 5 mice in the Tr- wild
type group. These data determine the dose response
nature of lung injury following exposure to bleomycin.
Lung fibrosis induced by 4500 IU bleomycin in the Tr-
wild type group was a mild patchy lung injury (Figure 5a).
Tr+ transgenic mice, following exposure to comparable
and smaller doses of bleomycin demonstrated marked
lung injury hallmarked by grossly thickened alveolar
walls, inflammation, fibroblast proliferation and collagen
deposition in a peribronchial, interstitial and sub pleural
distribution (Figure 5b).
To validate these tissue observations the fibrosis score in
bleomycin treated mice was determined as described. The
Tr+ transgenic-bleomycin group had greater fibrosis
scores (mean 1.88, SEM 0.27) than the Tr- wild type-ble-
omycin group (mean 0.875, SEM 0.295) (p < 0.05). Tr+
line 25-bleomycin group had the highest mean score
(mean 2.0, SEM 0.32) (p < 0.05) (Figure 5c) while the Tr+
line 18-bleomycin group also had a score of 1.75 (SEM
0.45). The PBS vehicle Tr- wild type group had scores of 0
(n = 8). These data further demonstrate the exacerbation
of bleomycin elicited lung injury in mice overexpressing
TGFβ1.
Finally, we determined the tissue distribution of TGFβ1 in
lung tissue from both Tr- wild type and Tr+ transgenic
mice following exposure to bleomycin. Immunostaining
for TGFβ1 demonstrated marked expression of TGFβ1 in
both wild type (Figure 6a) and Tr+ transgenic (Figure 6b)
mice following bleomycin exposure. Of note is the partic-
ularly strong expression in TGFβ1 transgenic mice, sug-
gesting that bleomycin exposure elicits a more
pronounced TGFβ1 response in Tr+ transgenic versus wild
type mouse lung.
Bleomycin induced pulmonary fibrosis in Tr+ mice 
enhances collagen deposition
Having determined the fibrotic response induced by expo-
sure to 4500 IU of bleomycin in both wild type and
TGFβ1 transgenic mouse lung tissue we further investi-
Table 1: Genes undergoing most significant upregulation in Bleomycin-exposed Tr+ TGFβ1 transgenic mice in compare to Tr+ 
untreated mice.
Accession No. Gene name SLRs
M12573.1 heat shock protein, 70 kDa 1 0.586101
BB746075 dipeptidyl peptidase 7 0.586311
X67128.1 rearranged T-cell receptor beta chain 0.586724
AF061744.1 FYN binding protein 0.588032
NM_010724.1 proteosome (prosome, macropain) subunit, beta type 8 0.590169
L42293.1 O-acyltransferase 1 (Soat1) 0.591774
NM_008979.1 protein tyrosine phosphatase, non-receptor type 8 0.592489
L78253.1 killer cell lectin-like receptor, subfamily A, member 8 0.597584
BB206460 phosphatidylinositol membrane-associated 0.599792
NM_009099.1 tripartite motif protein 30 0.600294
NM_007655.1 immunoglobulin-associated alpha (Iga) 0.600366
U29539.1 retinoic acid-inducible E3 protein 0.602024
BF301241 immunoglobulin kappa chain variable region 0.602451
M34563.1 CD28 antigen (Cd28) 0.602497
AW322280 keratin complex 2, basic, gene 8 0.60367
NM_009049.1 endocrine-specific protein 18 0.604619
BF301241 immunoglobulin kappa chain variable region 0.606074
NM_011487.1 signal transducer and activator of transcription 4 0.606996
BC002043.1 cyclin-dependent kinase inhibitor 1A 0.608647
M33266.1 small inducible cytokine B subfamily (Cys-X-Cys) 0.61223
AW227993 complement component 1, q subcomponent, beta polypeptide 0.612379
L05631.1 IL2-inducible T-cell kinase (Itk) 0.612786
NM_009952.1 cAMP response element binding protein (Creb1) 0.613665
AF274046.1 nuclear protein 95 (Np95) 0.615783
NM_010234.1 FBJ osteosarcoma oncogene 0.617241
NM_008328.1 interferon activated gene 203 0.617767
NM_011580.1 thrombospondin 1 0.621648
M26071.1 coagulation factor III 0.622067
AV075715 Clusterin 0.623468
BM124741 heat shock protein 25 kDa 2 0.625063Journal of Inflammation 2007, 4:18 http://www.journal-inflammation.com/content/4/1/18
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gated collagen production in lung tissue following expo-
sure to bleomycin.
De novo collagen production was assessed using hydroxy-
proline assay. The lung hydroxyproline content was
higher in the Tr+ transgenic-bleomycin group (mean 3.3
µg/mg, SEM 0.11) than in the Tr- wild type-bleomycin
group (mean 2.4 µg/mg, SEM 0.33)(p < 0.05) or the
unwounded PBS group (mean 1.76 µg/mg, SEM 0.16)
(Figure 6).
In summary, the fibrotic response in Tr+ transgenic mice
is dominated firstly by immune mediators reacting to ble-
omycin exposure and causing lung injury and secondly by
genes (TGFβ1) contributing to the deposition of extracel-
lular matrix. These data lend further weight to the hypoth-
esis that pulmonary fibrosis is a result of combined injury
from both endogenous and exogenous mediators and
provides important evidence for the interplay of these fac-
tors in the development of tissue fibrosis. Further analysis
of these transcriptomic alterations will reveal the exact
mechanism of the synergistic lung injury induced by
TGFβ1 overexpression and bleomycin injury.
Conclusion
In this study we have utilized transgenic mice to simulate
TGFβ1-related genetic predisposition to external stimuli,
rather than a tissue specific TGFβ1 transgenic model. We
have used a combination of gene overexpression and
exposure to an exogenous agent to further define the com-
plex nature of the initiation and progression of pulmo-
nary fibrosis. In common with most other complex
disorders, this data suggests that one single factor is insuf-
ficient to promote pulmonary fibrosis in isolation.
Increasing evidence has shown that it is the interplay of
myriad biological factors that promote the development
of this disease. TGFβ1 has been explored in depth in the
context of IPF due to its well-described pro-fibrotic injury.
In this study overexpression of the gene encoding TGFβ1
in mice was shown to initiate severe liver fibrosis as evi-
denced by histology. However, of note was the finding
that overexpression of the gene did not result in a de novo
fibrotic response in mouse lung. To probe the mechanism
at work in the lung we determined and showed that the
key components of TGFβ1 signalling were present in the
lung, despite the lack of fibrotic responses. This data
Table 2: Genes undergoing most significant downregulation in Bleomycin-exposed Tr+ TGFβ1 transgenic mice in compare to Tr+ 
untreated mice.
Accession No. Gene name SLRs
NM_033525.1 nephronectin -3.104277
NM_008508.1 loricrin -2.9579485
NM_008218.1 hemoglobin alpha, adult chain 1 -2.5698385
AF071431.1 beta globin -2.4558515
NM_009868.1 cadherin 5 -2.383406
NM_009502.1 vinculin -2.2180055
AB015595.1 calcitonin receptor-like receptor precursor -2.217319
BB623587 integrin alpha8 -2.155636
NM_007925.1 elastin -2.1294445
M34962.1 histocompatibility 2, L region -2.0658385
AW550625 procollagen, type III, alpha 1 -2.056252
X14480.1 nidogen 1 -2.027124
AK013851.1 G protein gamma 3 linked gene -1.928728
BG060909 stearoyl-Coenzyme A desaturase 2 -1.922733
BC004850.1 twisted gastrulation protein -1.854459
BE573195 epithelial membrane protein 2 -1.848788
AI324124 synuclein, alpha -1.80537
NM_008475.1 keratin complex 2, basic, gene 4 -1.7794
AB041350.1 type IV collagen alpha 5 chain -1.756065
BM211336 ferrochelatase -1.745825
AK013376.1 amyloid beta (A4) precursor-like -1.725242
NM_011594.1 tissue inhibitor of metalloproteinase 2 -1.705896
AF252873.1 CXC chemokine MIP-2gamma precursor -1.7039455
AY075134.1 T-box 4 -1.7018585
NM_009100.1 repetin -1.683903
NM_021099.2 kit oncogene -1.642024
BM239368 tumor differentially expressed 1 -1.6415555
U08020.1 collagen pro-alpha-1 type I chain m -1.6209215
AF128892.1 protein kinase Piccolo -1.615523
AF017989.1 secreted frizzled-related seq. protein 2 -1.5890315Journal of Inflammation 2007, 4:18 http://www.journal-inflammation.com/content/4/1/18
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TGFβ1 overexpression induces pronounced fibrotic response following bleomycin exposure Figure 5
TGFβ1 overexpression induces pronounced fibrotic response following bleomycin exposure. Tissue fibrosis was 
assessed in both Tr- wild type (A) and Tr+ transgenic (B) mice lung following exposure to 4500 IU bleomycin, as previously 
described. Shown are representative micrographs following haematoxylin/eosin staining of lung tissue, demonstrating fibrotic 
response in bleomycin treated wild type mouse lung that is significantly more severe in tissue from Tr+ TGFβ1 transgenic 
mice, suggesting that overexpression of the TGFβ1 transgene exacerbates subsequent lung injury. C. To quantify this fibrotic 
effect, fibrosis scores were determined as described. The graph shows enhanced fibrosis scores in Tr+ TGFβ1 transgenic mice 
versus their Tr- wild type counterparts in response to bleomycin exposure.Journal of Inflammation 2007, 4:18 http://www.journal-inflammation.com/content/4/1/18
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Enhanced TGFβ1 immunostaining and collagen production in bleomycin treated Tr+ TGFβ1 transgenic mice Figure 6
Enhanced TGFβ1 immunostaining and collagen production in bleomycin treated Tr+ TGFβ1 transgenic mice. 
A, B. To determine the role of TGFβ1 in the induction of lung fibrosis in mice treated with bleomycin, immunostaining for 
active TGFβ1 was performed as previously described. Shown are representative micrographs following immunostaining for 
TGFβ1 in the lung of bleomycin treated, Tr- wild type (A) and Tr+ TGFβ1 transgenic (B) mice. Expression of TGFβ1 is present 
in both tissue specimens but is substantially enhanced in the Tr+ TGFβ1 transgenic mice. C. Total collagen was determined by 
hydroxyproline assay as previously described. Collagen production was significantly enhanced in all bleomycin-wounded mice 
versus control PBS exposed, and in particular collagen deposition has been found higher in Tr+ TGFβ1 transgenic mice than in 
Tr- Wild Type ones. BLM, Bleomycin.Journal of Inflammation 2007, 4:18 http://www.journal-inflammation.com/content/4/1/18
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emphasises that a genetic predisposition in isolation is
insufficient to promote pulmonary fibrosis.
Despite several limitations [31], bleomycin-induced
fibrosis in an animal model is the most common method
for studying fibrosis. Some bleomycin-based model in
mice replicate human pathologic features of IPF, includ-
ing fibroproliferation within the lung parenchyma, and
hence pathologic mechanisms discerned in the mouse are
worthy of consideration, specifically it is recognized as a
source of epithelial cell injury which is considered central
to IPF in the human setting. The importance of TGFβ1 to
the development of lung fibrosis, was however, demon-
strated by the lung response to bleomycin. As compared
with their wild type treated counterparts, the transgenic
mice showed a much more severe fibrosis, as evidenced by
both histological analysis and deposition of collagen in
the lung. These data raise the possibility that overexpres-
sion of the TGFβ1 gene, in the germline, results in a sub-
sequent inappropriate response to bleomycin exposure.
This finding may explain a number of key features of the
disease including the susceptibility of some patients to
more severe progression and the multifactorial nature of
the pathology. Defects in the TGFβ1 gene resulting in
increased TGFβ1 production, or locally induced TGFβ1
increases may only be sufficient to cause a fibrotic injury
when acting in concert with other factors, thus reinforcing
the hypothesis that IPF development is due to the inter-
play of a number of factors.
We defined the fibrotic response in the transgenic animal
population following epithelial cell injury, and character-
ised the transcriptomic changes. The data showed distinct
patterns of gene expression driving the tissue response to
injury.
Chambers et al. have profiled human foetal lung fibrob-
last global gene expression in response to TGFβ1 revealing
the induction of Inhibitor of Differentiation-1 (ID1) and
providing evidence of smooth muscle cell phenotypic
switching [32]. Also, Liu et al. analyzed the lung gene
expression in bleomycin-exposed rats to identify genes
that may be involved in fibrosis, and identified FIZZ1 as
critical mediator in myofibroblast differentiation [33].
Our study demonstrated coordinate expression of distinct
gene families with the response dominated by mediators
of the immune response, suggesting the importance of
immunological events in the initiation of lung injury.
However, repetitive lung injury, that is the synergistic
activity of bleomycin and TGFβ1 led to a switch in this
transcriptomic response. The double injury mice were
characterised by molecular patterns that are hallmarks of
fibrosis, including extracellular matrix and cell growth
and regulation gene clusters. These data provide evidence
for the mechanism underpinning the exacerbated fibrosis
seen in transgenic mice at the tissue level. TGFβ1 overex-
pression primes the cellular machinery to produce a
fibrotic transcriptome when exposed to bleomycin
emphasising further the importance of this cytokine in the
development of tissue fibrosis. Although TGFβ1 is a criti-
cal initial key response factor after injury, it must be recog-
nised that in humans other cytokines including CTGF,
collagen and angiogenic mediators are involved in the
pathogenesis of pulmonary fibrosis.
Genes that encode for mediators of the immune response
(biological processes, defence response, humoral
immune response and inflammatory response) were
found to be altered in significant numbers in the setting of
the fibrotic lung. Exposure to this exogenous profibro-
genic agent elicits an immune response characterised by
upregulation of immune pathway genes [34]. Further-
more the development of tissue fibrosis has previously
been demonstrated to be a result of, at least in part, an
imbalance in the Th1/Th2 cytokine milieu, where the Th2
pro-fibrotic response is dominant [35].
Of note was the finding of a relatively large number of
development-associated genes whose expression was sig-
nificantly altered. The inappropriate recapitulation of
developmental processes has been shown to be a disease-
initiating event in the setting of renal fibrosis [36-38]. The
finding of these perturbed developmental networks in the
lung may indicate a similar role of development gone
awry in the setting of lung fibrosis.
These data demonstrate enhanced collagen deposition in
TGFβ1 transgenic mice compared to wild type mouse in
response to bleomycin wounding. This increase in colla-
gen production, coupled with the observed enhanced
active TGFβ1 immunostaining in transgenic mice provide
further evidence for the pathogenomic role of TGFβ1 in
the initiation and progression of lung fibrosis.
The data contained herein provide further evidence for the
complex interplay of numerous factors in the develop-
ment of IPF and provide evidence for the synergistic activ-
ity of genetic and exogenous mediators in eliciting fibrosis
in the lung. Further investigations will focus on character-
ising the combination of these factors in patients with IPF,
specifically with attention paid to the role of the TGFβ1
gene as a prime for subsequent lung injury.
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